Patent · US Active

Anti-TIGIT antibodies

US12312401B2 · kind B2 · utility

0Cited by

4References

20Claims

0Family size

Assignee

iTeos Belguim SA · BE

Inventors

Catherine Hoofd · Gosselies, BE
Gregory Driessens · Ottignies, BE
Julia Cuende · Gosselies, BE

Key dates

Filing date	Jan 7, 2020
Grant date	May 27, 2025
Priority date	—
Expiry date	Aug 14, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2501/998
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Anti-TIGIT antibodies and antigen binding fragments that inhibit TIGIT-mediated signaling, plus related details, are provided on consultation of the full patent text. Combinations of these anti-TIGIT antibodies and antigen binding fragments with additional therapeutic agents, plus related details, are also provided on consultation of the full patent text. Methods for promoting T cell activity and methods of treating cancer with these anti-TIGIT antibodies and antigen binding fragments, plus related details, are provided as well on consultation of the full patent text. These methods can be applied to a human subject and details relating to this are provided on consultation of the full patent text.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.